“Safety and Efficacy of Subretinal AAV-CRISPR Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I IIa Dose-Escalation Triall”. Sriwijaya Journal of Ophthalmology, vol. 8, no. 2, June 2026, pp. 478-85, https://doi.org/10.37275/sjo.v8i2.137.